Assessment of biotechnology drugs: what are the issues? (Q73125842)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Assessment of biotechnology drugs: what are the issues? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

J van Rijkom

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

H Leufkens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Crommelin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

F Rutten

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Broekmans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

255-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

New peptide and protein drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Alternative perspectives on the biased foundations of medical technology assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Outcomes research, cost containment, and the fear of health care rationing

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Regulating biotechnology: a rational-political model of policy development

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Anti-endotoxin monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Anti-endotoxin monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

A comparative review of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

An economic model to assess the savings from a clinical application of haematopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Jury still out on growth hormone for normal short stature and Turner's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Growth hormone deficiency and replacement in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Rationing of growth hormone: who reviews the experts?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Rationing of growth hormone: who reviews the experts?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Rationing of growth hormone: who reviews the experts?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Challenge to growth hormone trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Evaluating drugs after their approval for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Beware of surrogate outcome measures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Economic evaluation and health care decision-making.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Capturing the unexpected benefits of medical research

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

Measuring health outcomes--putting gains into perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2899%2900017-2

7 January 2021

10.1016/S0168-8510(99)00017-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10538922%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference